Biotechnology Industry Continues to Show Investors Strong Gains in 2012 -- Complete Genomics Soars on Strong Results
August 13 2012 - 8:20AM
Marketwired
The Biotechnology Industry has been soaring in 2012 as companies --
both large and small -- have shown impressive growth. The SPDR
S&P Biotech ETF (XBI) and the First Trust NYSE Arca Biotech
Index ETF (FBT) are up roughly 30 percent for the year,
outperforming the broader market by a wide margin. The Paragon
Report examines investing opportunities in the Biotechnology
Industry and provides equity research on Complete Genomics, Inc.
(NASDAQ: GNOM) and ImmunoGen, Inc. (NASDAQ: IMGN).
Access to the full company reports can be found at:
www.ParagonReport.com/GNOM
www.ParagonReport.com/IMGN
Despite having to negotiate a more challenging regulation
process biotech companies have continued to show investors strong
gains in 2012. The FDA Amendments Act of 2007 forced regulators to
increase standards for approvals of new drugs, introducing
mandatory risk evaluation and mitigation strategies. According to a
Pharmaceuticals & Biotechnology report from IMAP, several
pharmaceutical firms have altered their drug portfolios from
primary care driven blockbusters towards specialties such as
oncology, immunology and inflammation, where the medical need is
"so high that prices are more easily accepted by the
regulators."
Paragon Report releases regular market updates on the
Biotechnology Industry so investors can stay ahead of the crowd and
make the best investment decisions to maximize their returns. Take
a few minutes to register with us free at www.ParagonReport.com and
get exclusive access to our numerous stock reports and industry
newsletters.
Complete Genomics shares soared over 15 percent last Thursday
after reporting strong second quarter 2012 results. The company's
backlog as of June 30, 2012 was approximately 4,600 revenue
generating genomes, including approximately 1,000 genomes booked in
the second quarter, representing an aggregate revenue potential of
approximately $22 million.
ImmunoGen develops targeted anticancer therapeutics using the
Company's expertise in tumor biology, monoclonal antibodies, potent
cancer-cell killing agents and engineered linkers. The Company's
Targeted Antibody Payload (TAP) technology uses monoclonal
antibodies to deliver one of ImmunoGen's proprietary cancer-cell
killing agents specifically to tumor cells.
The Paragon Report has not been compensated by any of the
above-mentioned publicly traded companies. Paragon Report is
compensated by other third party organizations for advertising
services. We act as an independent research portal and are aware
that all investment entails inherent risks. Please view the full
disclaimer at: http://www.paragonreport.com/disclaimer
Add to Digg Bookmark with del.icio.us Add to Newsvine
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Sep 2024 to Oct 2024
Global X Genomics and Bi... (NASDAQ:GNOM)
Historical Stock Chart
From Oct 2023 to Oct 2024